{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25","upperLimit":"36.32","value":"32.025"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Number of months post-transplant until late relapse, in intervention patients relapsing after the 2-year primary study endpoint. Relapse defined as \\>5% blasts in bone marrow","dispersionType":"Full Range","groups":[{"description":"Group II (intervention): Patients undergo withdrawal of immunosuppression and receive donor lymphocyte infusions between days 60-365 post-transplant (or until full donor chimerism is achieved). Patients also undergo clinical monitoring and repeat chimerism testing as in group I.\n\nWithdrawal of immunosuppression and donor lymphocyte infusion: Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.","id":"OG000","title":"Group II: Intervention"}],"paramType":"MEAN","populationDescription":"intervention patients who relapsed after the 2 year primary study endpoint","reportingStatus":"POSTED","timeFrame":"24-36 months post-transplant","title":"Time Until Late Relapse","type":"POST_HOC","unitOfMeasure":"months"}